By Granite State Report — Breaking News & Investigations
CONCORD, N.H. — New Hampshire has spent the past decade at the jagged front of America’s overdose emergency. In 2024, for the first time in years, the state saw a meaningful drop in deaths — part of a historic nationwide decline — yet fentanyl and its dangerous additives still dominate the drug supply from Manchester to the North Country. The numbers show real progress. The street supply shows a moving target.
This is the story of two truths that now coexist in the Granite State: fatalities are falling — and the risk remains extreme.
The headline numbers: deaths are down, danger isn’t
The Centers for Disease Control and Prevention (CDC) reported a nearly 27% decline in U.S. overdose deaths in 2024, the largest one-year drop on record. New Hampshire was among the states with the steepest improvements, with declines of 35% or more compared to 2023. (CDC)
Inside New Hampshire, the picture sharpens. A statewide overview tallied 287 confirmed drug overdose deaths in 2024; 240 involved opioids/opiates and 218 were specifically fentanyl-class deaths. That means roughly three in four overdose fatalities last year involved fentanyl. (NH DHHS)
Those gains, while significant, sit atop a hard reality: fentanyl continues to dominate the illicit market. The New Hampshire Department of Safety’s public campaign summarizes it plainly — more than 80% of overdose deaths in 2023 involved fentanyl — a dominance that persisted into 2024. (New Hampshire Department of State)
And the drug itself hasn’t changed: fentanyl is 50–100 times more potent than morphine and about 50 times stronger than heroin, a margin of lethality that leaves little room for error. (National Institute on Drug Abuse)
What changed in 2024—and why the progress is fragile
Public-health analysts point to a confluence of factors behind the 2024 decline: wider access to naloxone, expanded treatment, settlement dollars funding services, and supply-side disruptions. National wire services and CDC briefings describe a rare, broad-based improvement across almost every state, including those hit hardest in recent years. Still, federal analysts caution that the trend is reversible if investments wane. (AP News)
New Hampshire’s own infrastructure matured at the same time:
- The Doorway network — nine regional hubs designed to be “less than an hour away” from anyone seeking help — has continued steering residents into care, a model DHHS has refined since its 2019 launch. (The Doorway)
- Naloxone (Narcan) and nalmefene are more accessible. In January 2024, DHHS issued standing orders authorizing any licensed pharmacist to dispense opioid antagonists, broadening walk-up access statewide. (NH DHHS)
- Syringe service programs (SSPs), authorized under state law, now function as crucial entry points for testing, wound care referrals, vaccinations, and treatment connections. (Justia Law)
- Drug-checking tools took a step forward: In 2023 New Hampshire decriminalized fentanyl and xylazine test strips; in 2024 the House advanced a broader drug-checking equipment bill to modernize testing as the supply evolves. (New Hampshire Bulletin)
These policy pivots did not happen in a vacuum. Public-health groups and national bodies — including CDC and SAMHSA — have urged states to legalize test strips and expand harm-reduction infrastructure as evidence-based measures that reduce deaths without increasing use. New Hampshire’s law joins a growing wave. (SAMHSA)
The fentanyl supply in New Hampshire: what’s on the street now
Fentanyl remains the main driver of overdose mortality in New Hampshire, but the supply is increasingly poly-drug — fentanyl mixed with stimulants (cocaine, methamphetamine) and non-opioid adulterants that complicate rescues.
- Illegally Manufactured Fentanyls (IMFs) continue to be detected in the majority of fatal overdoses across U.S. jurisdictions, with a significant presence in the Northeast. CDC surveillance shows the share of overdose deaths with IMFs increased sharply through 2023, with modest declines late in the year. (CDC)
- Xylazine, a veterinary sedative not reversed by naloxone, is increasingly found mixed with fentanyl in the Northeast. CDC and peer-reviewed studies document rising detection rates; local reporting in New Hampshire indicates xylazine has been detected statewide and in about 30% of fentanyl seizures in some analyses, heightening risks of deep tissue injury and prolonged sedation. (CDC)
- Local dashboards corroborate the pattern: Manchester’s public-health data hub aggregates AMR overdose responses, OCME confirmations, and trend lines that show fentanyl’s persistent role in the city’s burden. (City of Manchester)
Public-health alerts from New Hampshire’s Division of Public Health Services have warned clinicians about xylazine since early 2023, emphasizing wound care protocols, withdrawal management, and the need for drug-checking when possible. (NH DHHS)
Enforcement and the supply chain: what’s being stopped — and what isn’t
Law enforcement continues to seize fentanyl at the southern border and across New England; however, seizures don’t reliably translate to fewer deaths when production is cheap and distribution adaptable.
- U.S. Customs and Border Protection maintains a public dashboard on drug seizures, illustrating flows at land, air, and sea ports — with fentanyl representing a priority substance. (U.S. Customs and Border Protection)
- The DEA New England division has led frequent interdictions. In July 2025, federal prosecutors reported a 10-year sentence for a Manchester man for fentanyl trafficking — one in a string of federal cases targeting distribution in the Granite State. Earlier DEA releases underscore the agency’s long-held stance that enforcement alone cannot solve the crisis. (DEA)
- On the upstream end, precursor chemicals sourced from China and synthesis/pressing in Mexico continue to anchor congressional and executive branch attention. A nonpartisan Congressional Research Service brief details the evolving Mexico–China supply chain dynamics of illicit fentanyl and precursors feeding the U.S. market. Recent Treasury sanctions against Chinese chemical suppliers reflect the same pressure. (Congress.gov)
The takeaway for New Hampshire: supply is resilient. Even when large shipments are intercepted, the illicit market adapts — often substituting analogues or blending in new sedatives that resist naloxone and complicate medical care.
The economics: the crisis is expensive—even when deaths fall
The social and economic toll of the opioid epidemic is measured in hundreds of billions annually. Federal analyses have pegged the 2017 cost at roughly $1 trillion, with a $1.5 trillion estimate by 2020 as fentanyl overtook prescription opioids and heroin. Lost productivity, criminal-justice costs, child welfare, and health care spending all climb with overdose waves. That context matters as states deploy opioid settlement dollars and weigh where to invest next. (CDC)
Policy in practice: what New Hampshire has done — and what’s next
1) Widen the on-ramps to care
New Hampshire’s Doorway model remains the backbone of rapid access: a single call or walk-in to link people with medications for opioid use disorder (MOUD), detox, residential treatment, housing supports, and recovery coaching. The state’s DHHS maintains a public site outlining locations and 24/7 contact routes. (The Doorway)
What’s next: The model works best when transportation, housing, and post-detox stabilization are available; gaps in any one area can derail recovery. Advocates urge stable multi-year funding for peer recovery coaches, mobile MOUD, and rural coverage.
2) Maintain easy access to rescue medications
A January 2024 standing order authorizes pharmacists to dispense naloxone or nalmefene to anyone — individuals at risk, families, bystanders — without individual prescriptions. That reduces the friction at the counter and aligns with best practices nationally. (NH DHHS)
What’s next: Keep funding NaloxBox placements (wall-mounted rescue kits) and community trainings, and consider distribution at booking in jails and at ED discharge after nonfatal overdoses.
3) Keep harm reduction legal — and modernize it
HB 287 (2023) legalized possession of fentanyl and xylazine test strips by removing them from the definition of paraphernalia. In January 2024, the House passed HB 470, a bill to expand drug-checking equipment more broadly, reflecting a supply that now includes benzodiazepines, nitazenes, and sedatives that do not respond to naloxone. National trackers and public-health groups have pushed similar reforms across states. (New Hampshire Bulletin)
What’s next: Finish the job by legalizing comprehensive drug-checking, including spectrometry-based tools at supervised settings. Evidence indicates drug checking does not increase use and does reduce poisonings by changing behavior when contaminants are detected. (ACLU of New Hampshire)
4) Sustain syringe service programs (SSPs)
New Hampshire authorizes SSPs through statute and administrative rules. These programs reduce HIV/HCV transmission, provide wound care supplies, offer on-site naloxone, and — crucially — serve as trusted doorways to treatment. (Justia Law)
What’s next: Ensure stable funding, integrate onsite wound care for xylazine-related injuries, and co-locate MOUD initiation so people can start buprenorphine the same day.
5) Focus on rescuing the rescued
Nonfatal overdose is among the strongest predictors of a future fatality. Hospitals and EMS agencies increasingly use “warm handoffs” from the emergency department to peer recovery and MOUD appointments within 24–72 hours. Manchester’s dashboard demonstrates how local data can track these linkages over time and target hotspots for outreach. (City of Manchester)
What’s next: Make post-overdose home visits and mobile units standard statewide, with small grants for municipalities using local data to design outreach (e.g., post-OD check-ins with peers and clinicians).
The fentanyl-xylazine problem: why test strips matter
Naloxone reverses opioids; it does not reverse xylazine. That’s why responders now advise: always give naloxone, keep breathing for the person, and expect prolonged sedation if xylazine is on board. CDC clinical guidance and multiple studies show xylazine involvement climbing, concentrated in eastern states. New Hampshire health officials issued provider alerts and backed access to xylazine test strips (XTS) to identify contamination before use. (CDC)
Local reporting suggests xylazine has been detected in every New Hampshire county and appears with a significant share of fentanyl seizures — trends consistent with national surveillance. (WMUR)
Bottom line: In 2025, drug-checking is a life-saving technology, not a luxury. Even as deaths fall, the composition of the supply keeps shifting.
Enforcement notes: cases, capacity, and limits
Federal and state cases underscore the scale of local trafficking:
- Manchester has featured in several federal prosecutions. In July 2025, a 10-year federal sentence for a local man convicted of fentanyl distribution highlighted the continuing push by prosecutors and the DEA’s New England field division. (DEA)
- DOJ press releases detail ongoing arrests of alleged traffickers moving fentanyl and crack cocaine into the state, including a July 2025 arrest connected to Manchester. (Department of Justice)
At the same time, the DEA’s own communications acknowledge the limits of interdiction. In earlier regional operations, New England leadership emphasized that taking fentanyl off the street saves lives, but no one agency can “arrest our way out” of a dynamic supply. (DEA)
Community impact: classrooms, courtrooms, and kitchens
Behind every line on a chart is a family rearranging its life around addiction or grief. School counselors in mill towns now spend mornings managing trauma. Family courts juggle custody cases tied to relapse and recovery plans. Employers quietly build second-chance hiring pathways because the alternative is a shrinking labor force.
The Overdose Fatality Review Commission has urged cross-system fixes — improving data sharing, standardizing post-overdose referrals, and integrating care from ED discharge to housing support — so that the next contact with a system is a treatment opportunity, not another missed chance. (NH DHHS)
What a durable New Hampshire strategy looks like in 2025
1) Lock in the rescue infrastructure.
Make the pharmacy standing orders permanent and visible (window decals, website locators). Continue NaloxBox placements at libraries, town halls, and transit points. Equip more public buildings with bleed-control kits, AEDs, and naloxone side-by-side. (NH DHHS)
2) Finish modernizing drug-checking law.
Pass comprehensive drug-checking legislation so programs can test for benzodiazepines, nitazenes, and sedatives along with fentanyl — the substances driving non-naloxone-responsive overdoses. Align New Hampshire with best-practice states identified by national public-health law networks. (Network for Public Health Law)
3) Treat nonfatal overdose like a stroke.
Set statewide metrics: time-to-MOUD after ED discharge, appointment kept within 72 hours, peer contact within 24 hours, housing referral within a week. Tie settlement funding to meeting or exceeding those metrics.
4) Get real-time local intelligence to the street.
Leverage the Manchester Opioid Dashboard model to publish near-real-time alerts statewide — what’s circulating, where spikes are occurring, what contaminants are present — and route that intel to Doorway hubs, peers, and law enforcement simultaneously. (City of Manchester)
5) Keep interdiction focused on lethality.
Continue to prioritize high-purity and high-volume suppliers and pill-press operations, which maximize community harm, while ensuring diversion courts and treatment-first pathways are standard for low-level possession cases.
6) Fund wound care and xylazine-specific response.
Standing orders and naloxone are necessary but not sufficient when xylazine is involved. Fund mobile wound care, clinic pop-ups at SSPs, and training for EMS on sedation, hypoxia, and prolonged monitoring in polysubstance poisonings. (CDC)
Reader resource box: practical steps that save lives
- Carry naloxone (Narcan) — you can get it from many New Hampshire pharmacies under standing orders, no prescription needed. (NH DHHS)
- Assume fentanyl is present in non-prescribed pills and powders. Where available, use fentanyl and xylazine test strips before use; if positive, don’t use or use with medical precautions and never alone. (SAMHSA)
- In an overdose: call 911, give naloxone, keep breathing for the person (rescue breaths), and monitor — especially if xylazine might be present, because sedation can persist after breathing returns. (CDC)
- Need help now? The state’s Doorway network provides 24/7 connections to treatment and support. (The Doorway)
Why this still matters — even in a “good year”
Progress in 2024 offers a template: harm reduction works, treatment access works, data-driven outreach works. But fentanyl is a chemical — cheap to make, easy to press, and ruthlessly efficient at finding demand. The drug supply keeps changing (with sedatives like xylazine and occasional appearances of nitazene-class opioids), and community fatigue is real.
The lesson for New Hampshire is as pragmatic as the state itself: we can hold two ideas at once — celebrate the lives saved and behave like the emergency continues. Because it does.
Sources & further reading
New Hampshire & local data
- NH DHHS — Drug Monitoring Initiative (DMI), 2024–2025: 2024 overview and monthly updates, including counts and fentanyl involvement. (NH DHHS)
- NH Department of Safety — “No Safe Experience” public information campaign (fentanyl share of deaths). (New Hampshire Department of State)
- NH OCME (Office of the Chief Medical Examiner) — Drug death data updates and publications. (New Hampshire Department of Justice)
- Manchester Opioid Dashboard — city-level overdose and response trends. (City of Manchester)
- Governor’s Office — 2024 overdose data summary (drug categories, fentanyl-class deaths). (New Hampshire Governor’s Office)
- Overdose Fatality Review Commission — Annual report (2024). (NH DHHS)
National trends & clinical guidance
- CDC — Press release (May 14, 2025): U.S. overdose deaths decreased ~27% in 2024; NH among largest declines. (CDC)
- Associated Press (context on 2024 decline). (AP News)
- CDC NVSS — Provisional overdose count dashboard. (CDC)
- NIDA / DEA — Fentanyl potency and risks. (National Institute on Drug Abuse)
- CDC — Fentanyl facts. (CDC)
- CDC — Xylazine: clinical and harm-reduction guidance. (CDC)
- CDC MMWR — IMF detection trends (2021–2024). (CDC)
- JAMA Network Open (2023) — Xylazine trends concentrated in eastern states. (JAMA Network)
Law & policy
- HB 287 (2023) — Decriminalized fentanyl and xylazine test strips in NH; coverage and bill text. (New Hampshire Bulletin)
- HB 470 (2024) — House-passed expansion to broader drug-checking equipment. (New Hampshire Bulletin)
- Network for Public Health Law (2024/2025) — 50-state drug-checking fact sheets (NH limits and national context). (Network for Public Health Law)
- Naloxone & nalmefene standing orders (2024) — DHHS policy and reporting. (NH DHHS)
- Syringe service program statutes & guidance — NH RSA 318-B:43 et seq.; DHHS program materials. (Justia Law)
Enforcement & supply chain
- CBP — Drug Seizure Statistics. (U.S. Customs and Border Protection)
- DEA New England — Manchester trafficking sentence (2025). (DEA)
- DOJ — Manchester-linked fentanyl trafficking arrest (2025). (Department of Justice)
- DEA (2019 New England operation) — context on enforcement posture. (DEA)
- Congressional Research Service (2025) — Illicit fentanyl and Mexico’s role; supply chain briefing. (Congress.gov)
- U.S. Treasury OFAC (2025) — Sanctions on Chinese chemical supplier linked to precursor trade. (U.S. Department of the Treasury)
Editorial Note to Readers
Granite State Report treats overdose coverage as ongoing, public-service journalism. The data above rely on provisional and finalized sources; local counts can be revised as investigations close. We link directly to state dashboards, OCME/DHHS reports, and federal datasets so readers can explore the underlying numbers and methods.
If you have a tip about fentanyl trends, rescue access, or treatment gaps in your town, email our newsroom. If you need help now, contact The Doorway for 24/7 assistance. (The Doorway)
This feature is part of Granite State Report’s breaking-news coverage of the fentanyl crisis in New Hampshire. It may be updated as new data become available.
